Abstract
Objective: This study aimed to evaluate the efficacy of Centella asiatica leaf extract in maintaining calcium and phosphate levels in the bone forpreventing osteoporosis in postmenopausal women.Methods: The obtained C. asiatica leaf extract was administered to ovariectomized rats at the doses of 60, 120, and 180 mg/kg body weight (BW)for 30 days. Subsequently, the rats were euthanized by ether overdose, and bone calcium and phosphate levels were determined by the wet ashingtechnique and spectrophotometry.Results: The results showed no significant differences in the bone calcium and phosphate levels among rats administered with different doses ofC. asiatica leaf extract.Conclusion: Our results indicate that C. asiatica leaf extract cannot be used as a source of phytoestrogens to maintain calcium and phosphate levelsin the bones.
Highlights
Osteoporosis is a chronic and progressive disease characterized by low bone mass, bone microstructure disorder, and decreased bone strength that causes brittleness and susceptibility to bone fracture [1]
Building on the previous studies on the properties of compounds found in C. asiatica, the present study aimed to evaluate the efficacy of C. asiatica leaf extract in maintaining calcium and phosphate levels in the bone for preventing osteoporosis in postmenopausal women, as well as to determine the optimal dose
One-way analysis of variance (ANOVA) revealed no significant difference in calcium levels among the treatment groups
Summary
Osteoporosis is a chronic and progressive disease characterized by low bone mass, bone microstructure disorder, and decreased bone strength that causes brittleness and susceptibility to bone fracture [1]. It is associated with old age and has become a major health problem worldwide, including in developed countries, especially in postmenopausal women [2]. Two types of cytokines are produced by bone marrow stromal cells and osteoblasts that are essential in osteoclastogenesis induced by macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand (RANKL), which are members of the tumor necrosis factor (TNF) superfamily. RANKL is expressed by mononuclear osteoclast precursors that play a role in osteoclast formation, whereas osteoprotegerin (OPG) is produced by stromal and osteoblast cells and is a natural inhibitor of RANKL and, antagonistic to the osteoclastogenic activity of RANKL [4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
